Axsome Therapeutics, Inc. (AXSM) Form 8-K — Aug 10, 2026
Axsome Therapeutics reported second quarter 2026 total net product revenue of $218.4 million, up 46% year over year, with a net loss of $51.3 million, or $(0.99) per share, versus a $48.0 million loss a year ago. AUVELITY drove the quarter with $180.3 million in net sales, up 51% year over year, following its June 2026 launch for agitation associated with dementia due to Alzheimer's disease, while SUNOSI added $35.8 million (+20% YoY) and the newer SYMBRAVO contributed $2.3 million (+461% YoY).
Key figures
- Revenue
- 218400000
- Guidance
- Axsome believes current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
- Total Debt
- 190000000
- Revenue Yoy
- 46%
- Total Assets
- 761447000
- Cash Position
- 319850000
- Shares Outstanding
- 52299889
- Market cap
- $11.0B as of August 7, 2026
- Sunosi trx
- ~61,000 (+14% YoY)
- Rnd expense
- $46.2M (vs $49.5M in 2Q 2025)
- Auvelity trx
- ~266,000 (+34% YoY, +12% QoQ)
- Sgna expense
- $208.1M (vs $130.3M in 2Q 2025, +60%)
- Symbravo trx
- ~23,500 (+30% QoQ)
- Pdufa date axs12
- May 1, 2027 (cataplexy in narcolepsy)
- Stock based comp
- $27.1M in 2Q 2026
- Auvelity net sales
- $180.3M (+51% YoY)
- Sunosi net revenue
- $35.8M (+20% YoY)
- Symbravo net sales
- $2.3M (+461% YoY)
- Prior year net loss
- $48.0M, $(0.97) per share
- Auvelity nbrx 65plus
- +126% in first 8 weeks post Alzheimer's agitation launch
- Auvelity payer coverage
- ~89% of lives
- Marketed product opportunity
- ~$9.5B total commercial opportunity
- Pipeline peak sales potential
- >$18B annual
Price after filing
Close on the filing date to close N calendar days later (from $212.74). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.